Program
Midazolam
Also written as “midazolam”, “USL261” and “SHP615”.
Its studies are mostly in Epilepsy · HIV Infections · Diabetes Mellitus, Type 2 · Neoplasms · Nervous System Diseases, led by 10 companies.
Drug pageMidazolam: every studyMany companies study it; this page follows only the 18 they lead. All 426 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 30 open or running | phase 1since Jul 1, 2008 | Jul 1, 2008 | none ahead |
| Merckits history only | 30 open or running | phase 1since Jun 17, 2015 | Jun 17, 2015 | none ahead |
| Takeda | 30 open or running | phase 3since Nov 6, 2017 | Nov 6, 2017 | none ahead |
| Hamad Medicalits history only | 20 open or running | phase 4since Sep 4, 2016 | Sep 4, 2016 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 1since Oct 2, 2015 | Oct 2, 2015 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 1since Aug 9, 2018 | Aug 9, 2018 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 10 open or running | phase 3since May 31, 2007 | May 31, 2007 | none ahead |
| Phathom Pharmaceuticalsits history only | 10 open or running | phase 1since Sep 4, 2020 | Sep 4, 2020 | none ahead |
| Rafa Laboratoriesits history only | 10 open or running | phase 1since Dec 15, 2020 | Dec 15, 2020 | none ahead |
| The Emmesits history only | 10 open or running | phase 3since Apr 27, 2005 | Apr 27, 2005 | none ahead |
Also a collaborator on its studies: Arvinas Estrogen Receptor, National Resilience, Takeda Development Center Americas, PRA Health Sciences, Medpace, Premier Research Group and Cross Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 6, 2017First studies: 2 phase 3 studies in Nervous System DiseasesFirst studyNCT03336645, NCT03336450
- Jan 29, 2018Phase 1 study in CarcinomaNCT03420742 · 24 enrolled · France, Italy, Netherlands and more
TargetBeta
“GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule
Other programs on the same 16 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ciprofolrule | Haisco Pharmaceutical Group | phase 4 | 36 |
| Alprazolamrule | Viatris | phase 4 | 35 |
| brexanolonerule | Supernus Pharmaceuticals | phase 4 | 14 |
| Diazepamrule | Acorda Therapeutics | phase 3 | 9 |
Studies
All 3 Takeda leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03420742Carcinoma · France, Italy, Netherlands and more | 1 | Completed | Mar 24, 2020 | 24 |
| NCT03336645Nervous System Diseases · Japan | 3 | Completed | Aug 19, 2019 | 25 |
| NCT03336450Nervous System Diseases · Japan | 3 | Completed | Oct 13, 2020 | 3 |
How it is read
Names in the registry
- “Midazolam”, 64 entries
- “midazolam”, 13 entries
- “USL261”, 4 entries
- “SHP615”, 2 entries
- “Midazolam Solution”, 1 entry
Conditions, from the studies’ own filings
- Epilepsy, 4 studies
- HIV Infections, 2 studies
- Diabetes Mellitus, Type 2, 2 studies
- Neoplasms, 2 studies
- Nervous System Diseases, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.